Cutia Therapeutics (HKSE:02487) Other Financing: HK$234.1 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:02487 Cutia Therapeutics HKSE:02487
40 GF Score
Price HK$2.61
GF Value HK$16.27
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Cutia Therapeutics Other Financing?

Cutia Therapeutics HKSE:02487 +6.10% 40 Other Financing is HK$234.1 Mil as of Dec. 2025. GuruFocus rates HKSE:02487 with a GF Score™ of 40/100 and a GF Value™ of HK$16.27 (Possible Value Trap). The stock has 4 warning signs investors should review.

Cutia Therapeutics's Other Financing for the six months ended in Dec. 2025 was HK$238.7 Mil.

Cutia Therapeutics's Other Financing for the trailing twelve months (TTM) ended in Dec. 2025 was HK$234.1 Mil.

Cutia Therapeutics Other Financing Historical Data

* Premium members only.

The historical data trend for Cutia Therapeutics's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cutia Therapeutics Other Financing Chart

Cutia Therapeutics Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Other Financing
-0.18 -3.76 -12.94 -14.29 -10.38

Cutia Therapeutics Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Financing Get a 7-Day Free Trial Premium Member Only -5.81 -11.44 -17.75 -4.57 238.72
HKSE:02487
40GF Score
Cutia Therapeutics HKSE:02487
Other Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cutia Therapeutics Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$234.1 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of HK$234.1 Mil mean?
Cutia Therapeutics (HKSE:02487) has a Other Financing of HK$234.1 Mil as of Dec. 2025. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Cutia Therapeutics and its competitors.
Is Cutia Therapeutics' Other Financing too high?
Cutia Therapeutics' current Other Financing is HK$234.1 Mil. Overall, Cutia Therapeutics has a GF Score™ of 40/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Cutia Therapeutics' Other Financing compare to VRTX and REGN?
Cutia Therapeutics' Other Financing of HK$234.1 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Biotechnology company?
A good Other Financing depends on the Biotechnology industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Cutia Therapeutics and its competitors. Cutia Therapeutics's current Other Financing is HK$234.1 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cutia Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Cutia Therapeutics (HKSE:02487) is currently considered Possible Value Trap. The stock's GF Value™ is HK$16.27, compared to a current price of HK$2.61 — trading 84% below its estimated fair value. The current Other Financing is HK$234.1 Mil. Cutia Therapeutics' overall GF Score™ is 40/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For Cutia Therapeutics (HKSE:02487), the current Other Financing is HK$234.1 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cutia Therapeutics (HKSE:02487) Overvalued in 2026?

Based on GuruFocus' analysis, Cutia Therapeutics stock appears to be undervalued. The current stock price of HK$2.61 is trading 84% below its estimated GF Value™ of HK$16.27. GuruFocus considers Cutia Therapeutics to be Possible Value Trap.

Key valuation signals for HKSE:02487:

  • Other Financing: HK$234.1 Mil
  • GF Value™: HK$16.27 vs. price of HK$2.61 (84% below fair value)
  • GF Score™: 40/100 with 4 warning signs

No single metric tells the full story. See the HKSE:02487 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cutia Therapeutics Business Description

Address 436 Heng Feng Road, 20th Floor, Huanzhi Building, Jingan District, Shanghai, CHN, 200070
Cutia Therapeutics is an investment holding company. The Company and its subsidiaries are principally engaged in developing inventive and comprehensive solutions that are tailored to meet the diverse and evolving needs of patients and consumers in the broader dermatology treatment and care market. It has a proprietary CATAME technology platform, which includes: Colloidal-Emulsification-Active Encapsulation (CEAE) platform, Aerosol (ARS) platform, Transdermal Delivery (TDD) platform, Actives & Formulation Evaluation (AFE) platform, Micro/Nano-Particulates & Self-Assembly (MiSA) platform, and Ex vivo & Efficacy Evaluation (EVEE) platform. It enables the development of a wide range of product dosage forms and the relevant formulation technology.
40GF Score

Get the complete analysis for HKSE:02487

Other Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$2.61
Price
HK$16.27
GF Value